Mode
Text Size
Log in / Sign up

Nomogram Predicts Osteoporosis Risk in Rheumatoid Arthritis Patients

Nomogram Predicts Osteoporosis Risk in Rheumatoid Arthritis Patients
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider using this nomogram cautiously for osteoporosis risk stratification in RA patients pending external validation.

This single-center retrospective study developed a nomogram prediction model for osteoporosis risk in rheumatoid arthritis (RA) patients. The study included 349 RA patients with available dual-energy X-ray absorptiometry (DXA) data. The overall prevalence of osteoporosis was 37.8% (132/349). In the training cohort (n=250), prevalence was 36.8% (92/250), and in the validation cohort (n=99), it was 40.4% (40/99).

Independent predictors of osteoporosis identified were female sex, higher Health Assessment Questionnaire Disability Index (HAQ-DI), elevated alkaline phosphatase (ALP), increased apolipoprotein A1/apolipoprotein B (ApoA1/ApoB) ratio, higher free fatty acids (FFA), and lower body mass index (BMI). The model demonstrated good discrimination with an area under the receiver operating characteristic curve (AUROC) of 0.812 in the training set and 0.788 in the validation set. Calibration was adequate (Hosmer-Lemeshow test p > 0.05). Decision curve analysis and risk stratification showed statistically significant odds ratios for medium and high-risk groups.

Safety and tolerability were not reported as this was a prediction model study without interventions. Key limitations include the model's unknown performance in diverse populations and the need for prospective multicenter external validation before any clinical application. The nomogram may facilitate targeted screening and early intervention for osteoporosis in RA patients, but clinicians should interpret results cautiously until further validation is available.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundRheumatoid arthritis (RA) increases the risk of osteoporosis, but tools that integrate RA-specific clinical and metabolic factors to predict osteoporosis risk are limited. We aimed to develop and validate a practical risk prediction nomogram for osteoporosis in RA patients.MethodsIn this single-center retrospective study, 349 RA patients with available DXA data were analyzed; 132 (37.8%) had osteoporosis. A training cohort (n = 250; osteoporosis = 92) and a temporal validation cohort (n = 99; osteoporosis = 40, enrolled later in the study period) were used. Candidate predictors included clinical, functional, and laboratory variables. Stepwise backward logistic regression identified independent predictors that were incorporated into a nomogram. Model performance was assessed by discrimination (AUROC), calibration (calibration curve and Hosmer–Lemeshow test), decision curve analysis (DCA), and risk stratification.ResultsFemale sex, higher health assessment questionnaire-disability index (HAQ-DI), elevated alkaline phosphatase (ALP), increased ApoA1/ApoB ratio, higher free fatty acids (FFA), and lower body mass index (BMI) were independent predictors of osteoporosis and were included in the nomogram. The model yielded AUROCs of 0.812 (training) and 0.788 (validation), showed good calibration (Hosmer–Lemeshow p > 0.05), and provided positive net benefit across a range of threshold probabilities in DCA. Nomogram-based risk strata (low/medium/high) discriminated osteoporosis risk with statistically significant odds ratios for medium and high groups.ConclusionThe proposed nomogram, built from readily available clinical and laboratory measures, demonstrates good discrimination, calibration, and clinical utility for identifying RA patients at elevated risk of osteoporosis, and may facilitate targeted screening and early intervention. However, the model’s performance in diverse populations remains unknown, and prospective multicenter external validation is essential before any clinical application.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.